DDrare: Database of Drug Development for Rare Diseases

76. 下垂体性ゴナドトロピン分泌亢進症
［臨床試験数：25，薬物数：41（DrugBank：11），標的遺伝子数：3，標的パスウェイ数：10］

Searched query = "Pituitary gonadotropin secretion hyperthyroidism", "Gonadotropin secreting pituitary adenoma", "Central precocious puberty", "Gonadotropin producing pituitary adenoma"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = Acetate; CPP; Dabu ying pills; Dihuang; Enantone; GnRH; GnRH agonist; Gold; Gonadorelin; Gonadorelin acetate and Triptorelin acetate; Histrelin; Histrelin Subcutaneous Implant; LA; LEUPRORELIN ACETATE; Leuplin; Leuplin DPS 11.25mg; Leuprolide; Leuprolide (GnRH agonists); Leuprolide Acetate (LA); Leuprolide Acetate 3 Month Depot; Leuprolide Acetate 45 mg; Leuprolide acetate 11.25 mg; Leuprolide acetate 30 mg; Leuprolide acetate depot; Leuprorelin; Leuprorelin Acetate 3.75mg Injection; Luphere depot 3.75mg(Leuprolide acetate 3.75mg); Lupron (leuprolide acetate); Megestrol Acetate Tablet; Megestrol acetate; RhGH; TRIPTORELIN; Trade name depends on the source of the product; Trade name depends on the source of the product’; Triptorelin; Triptorelin (GnRH agonists); Triptorelin acetate and Gonadorelin acetate; Triptorelin embonate, Triptorelin pamoate; Triptorlin or Leuprorelin; Zhibo dihuang pills; Ziyinxiehuo Granules Herbs

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02993926 (ClinicalTrials.gov)	June 24, 2017	13/12/2016	A Study to Assess the Safety and Efficacy of Enantone (Leuprorelin) in Central Precocious Puberty (CPP) Among Chinese Participants	An Observational, Retrospective Study to Evaluate the Long Term Safety and Effectiveness of Leuprorelin in the Treatment of Central Precocious Puberty	Puberty, Central Precocious	Drug: Enantone;Drug: GnRH agonist	Takeda	NULL	Completed	N/A	N/A	All	108		China
2	NCT00438217 (ClinicalTrials.gov)	May 2006	21/2/2007	Analysis of Genetic and Environmental Parameters Influencing Growth Rate of Precocious Puberty Children	Analysis of Genetic and Environmental Parameters Influencing Growth Rate of Precocious Puberty Children	Central Precocious Puberty	Drug: Triptorelin (GnRH agonists);Drug: Leuprolide (GnRH agonists)	University of Pisa	NULL	Recruiting	1 Year	18 Years	Both	100	Phase 4	Italy

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT02993926
(ClinicalTrials.gov)

June 24, 2017

13/12/2016

A Study to Assess the Safety and Efficacy of Enantone (Leuprorelin) in Central Precocious Puberty (CPP) Among Chinese Participants

An Observational, Retrospective Study to Evaluate the Long Term Safety and Effectiveness of Leuprorelin in the Treatment of Central Precocious Puberty

Puberty, Central Precocious

Drug: Enantone;Drug: GnRH agonist

Takeda

NULL

Completed

N/A

All

108

China

NCT00438217
(ClinicalTrials.gov)

May 2006

21/2/2007

Analysis of Genetic and Environmental Parameters Influencing Growth Rate of Precocious Puberty Children

Central Precocious Puberty

Drug: Triptorelin (GnRH agonists);Drug: Leuprolide (GnRH agonists)

University of Pisa

NULL

Recruiting

1 Year

18 Years

Both

100

Phase 4

Italy